33
Views
2
CrossRef citations to date
0
Altmetric
Review

Bone density in children treated with gonadotropin-releasing hormone analogs for central precocious puberty

, , , , , , , , , , & show all
Pages 285-290 | Published online: 10 Jan 2014

References

  • Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch. Dis. Child.90, 373–378 (2005).
  • Gordon CM, Bachrach LK, Carpenter TO et al. Dual energy x-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J. Clin. Densitom.11, 43–58 (2008).
  • Baim S, Leonard MB, Bianchi ML et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD Pediatric Position Development conference. J. Clin. Densitom.11, 6–21 (2008).
  • Kalkwarf HJ, Zemel BS, Gilsanz V et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J. Clin. Endocrinol. Metab.92, 2087–2099 (2007).
  • Loomba-Albrecht LA, Styne DM. Effect of puberty on body composition. Curr. Opin. Endocrinol. Diabetes. Obes.16, 10–15 (2009).
  • Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev.23, 279–302 (2002).
  • Christo K, Prabhakaran R, Lamparello B et al. Bone metabolism in adolescent athletes with amenorrhea, athletes with eumenorrhea, and control subjects. Pediatrics121, 1127–1136 (2008).
  • Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst. Rev.4, CD001297 (2003).
  • Schoenau E. Bone mass increase in puberty: what makes it happen? Horm. Res.65(Suppl. 2), 2–10 (2006).
  • Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm. Res.71, 290–297 (2009).
  • Chevalley T, Bonjour JP, Ferrari S, Rizzoli R. Influence of age at menarche on forearm bone microstructure in healthy young women. J. Clin. Endocrinol. Metab.93, 2594–2601 (2008).
  • Chevalley T, Rizzoli R, Hans D, Ferrari S, Bonjour JP. Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche. J. Clin. Endocrinol. Metab.90, 44–51 (2005).
  • Carel JC, Eugster EA, Rogol A et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics123, E752–E762 (2009).
  • Takahashi Y, Minamitani K, Kobayashi Y, Minagawa M, Yasuda T, Niimi H. Spinal and femoral bone mass accumulation during normal adolescence: comparison with female patients with sexual precocity and with hypogonadism. J. Clin. Endocrinol. Metab.81, 1248–1253 (1996).
  • Saggese G, Bertelloni S, Baroncelli GI, Battini R, Franchi G. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur. J. Pediatr.152, 717–720 (1993).
  • Antoniazzi F, Bertoldo F, Zamboni G et al. Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur. J. Endocrinol.133, 412–417 (1995).
  • Neely EK, Bachrach LK, Hintz RL et al. Bone mineral density during treatment of central precocious puberty. J. Pediatr.127, 819–822 (1995).
  • Arisaka O, Hoshi M, Kanazawa S et al. Preliminary report: effect of adrenal androgen and estrogen on bone maturation and bone mineral density. Metabolism50, 377–379 (2001).
  • Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin. Endocrinol.56, 129–148 (2002).
  • Verrotti A, Chiarelli F, Montanaro AF, Morgese G. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog. Gynecol. Endocrinol.9, 277–281 (1995).
  • Ruiz-Echarri M, Ferrández Longás A, Mayayo Dehesa E. Bone mass evolution in patients with precocious and advanced puberty treated with LHRH analogs. Ann. Esp. Pediatr.51, 499–504 (1999).
  • Unal O, Berberoglu M, Evliyaoglu O, Adiyaman P, Aycan Z, Ocal G. Effects on bone mineral density of gonadotropin releasing hormone analogs used in the treatment of central precocious puberty. J. Pediatr. Endocrinol. Metab.16, 407–411 (2003).
  • Antoniazzi F, Zamboni G, Bertoldo F et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J. Clin. Endocrinol. Metab.88, 1096–1101 (2003).
  • Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur. J. Pediatr.157, 363–367 (1998).
  • Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J. Clin. Endocrinol. Metab.84, 4583–4590 (1999).
  • van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J. Clin. Endocrinol. Metab.87, 506–512 (2002).
  • Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur. J. Pediatr.159, 369–374 (2000).
  • Tung YC, Lee JS, Tsai WY, Hsiao PH. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J. Formos. Med. Assoc.106, 826–831 (2007).
  • Wacharasindhu S, Petwijit T, Aroonparkmongkol S, Srivuthana S, Kingpetch K. Bone mineral density and body composition in Thai precocious puberty girls treated with GnRH agonist. J. Med. Assoc. Thai.89, 1194–1198 (2006).
  • Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J. Clin. Endocrinol. Metab.93, 190–195 (2008).
  • Kapteijns-van Kordelaar S, Noordam K, Otten B, van den Bergh J. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature. Eur. J. Pediatr.162, 776–780 (2003).
  • Yanovski JA, Rose SR, Municchi G et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N. Engl. J. Med.348, 908–917 (2003).
  • van Gool SA, Kamp GA, Visser-van Balen H et al. Final height outcome after three years of GH and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J. Clin. Endocrinol. Metab.92, 1402–1408 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.